• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

放射性标记小分子蛋白激酶抑制剂用于 PET 或 SPECT 成像。

Radiolabeled small molecule protein kinase inhibitors for imaging with PET or SPECT.

机构信息

Department of Psychiatry, University of Toronto, Toronto, ON, Canada.

出版信息

Molecules. 2010 Nov 15;15(11):8260-78. doi: 10.3390/molecules15118260.

DOI:10.3390/molecules15118260
PMID:21079565
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6259110/
Abstract

Imaging protein kinase expression with radiolabeled small molecule inhibitors has been actively pursued to monitor the clinical potential of targeted therapeutics and treatments as well as to determine kinase receptor density changes related to disease progression. The goal of the present review is to provide an overview of the breadth of radiolabeled small molecules that have been synthesized to target intracellular protein kinases, not only for imaging in oncology, but also for other areas of interest, particularly the central nervous system. Considerable radiotracer development has focused on imaging receptor tyrosine kinases of growth factors, protein kinases A, B and C, and glycogen synthase kinase-3ß. Design considerations, structural attributes and relevant biological results are summarized.

摘要

用放射性标记的小分子抑制剂来成像蛋白激酶的表达一直受到积极的研究,以监测靶向治疗和治疗的临床潜力,以及确定与疾病进展相关的激酶受体密度变化。本综述的目的是提供一个广泛的综述,介绍了为靶向细胞内蛋白激酶而合成的放射性标记小分子,不仅用于肿瘤学成像,还用于其他感兴趣的领域,特别是中枢神经系统。大量的放射性示踪剂开发集中在成像生长因子的受体酪氨酸激酶、蛋白激酶 A、B 和 C 以及糖原合酶激酶-3β。总结了设计考虑因素、结构属性和相关的生物学结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3804/6259110/4c8af9a43da7/molecules-15-08260-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3804/6259110/8c0e6cb7ae01/molecules-15-08260-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3804/6259110/531955669863/molecules-15-08260-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3804/6259110/a2de6eac231f/molecules-15-08260-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3804/6259110/c5060396e5fb/molecules-15-08260-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3804/6259110/950aac3a2a7b/molecules-15-08260-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3804/6259110/8af03dcb9f99/molecules-15-08260-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3804/6259110/492f47f0ba81/molecules-15-08260-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3804/6259110/74bca638fb04/molecules-15-08260-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3804/6259110/4c8af9a43da7/molecules-15-08260-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3804/6259110/8c0e6cb7ae01/molecules-15-08260-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3804/6259110/531955669863/molecules-15-08260-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3804/6259110/a2de6eac231f/molecules-15-08260-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3804/6259110/c5060396e5fb/molecules-15-08260-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3804/6259110/950aac3a2a7b/molecules-15-08260-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3804/6259110/8af03dcb9f99/molecules-15-08260-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3804/6259110/492f47f0ba81/molecules-15-08260-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3804/6259110/74bca638fb04/molecules-15-08260-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3804/6259110/4c8af9a43da7/molecules-15-08260-g009.jpg

相似文献

1
Radiolabeled small molecule protein kinase inhibitors for imaging with PET or SPECT.放射性标记小分子蛋白激酶抑制剂用于 PET 或 SPECT 成像。
Molecules. 2010 Nov 15;15(11):8260-78. doi: 10.3390/molecules15118260.
2
Some implications of receptor kinase signaling pathway for development of multitargeted kinase inhibitors.受体激酶信号通路对多靶点激酶抑制剂开发的一些启示。
Curr Radiopharm. 2013 Mar;6(1):48-55. doi: 10.2174/1874471011306010008.
3
Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET Imaging.用于PET成像的放射性标记激酶抑制剂的研发与应用的最新进展
Molecules. 2015 Dec 9;20(12):22000-27. doi: 10.3390/molecules201219816.
4
Radiolabeled glucose derivatives for tumor imaging using SPECT and PET.放射性标记的葡萄糖衍生物用于 SPECT 和 PET 肿瘤成像。
Curr Med Chem. 2014;21(1):24-34. doi: 10.2174/09298673113209990254.
5
Imaging COX-2 expression in cancer using PET/SPECT radioligands: current status and future directions.使用PET/SPECT放射性配体对癌症中COX-2表达进行成像:现状与未来方向
J Labelled Comp Radiopharm. 2014 Apr;57(4):317-22. doi: 10.1002/jlcr.3160. Epub 2013 Dec 18.
6
PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET.正电子发射断层扫描用小分子酪氨酸激酶抑制剂:TKI-PET。
Drug Discov Today. 2012 Nov;17(21-22):1175-87. doi: 10.1016/j.drudis.2012.06.016. Epub 2012 Jul 2.
7
A tyrosine kinase inhibitor-based high-affinity PET radiopharmaceutical targets vascular endothelial growth factor receptor.一种基于酪氨酸激酶抑制剂的高亲和力正电子发射断层显像(PET)放射性药物靶向血管内皮生长因子受体。
J Nucl Med. 2014 Sep;55(9):1525-31. doi: 10.2967/jnumed.114.138925. Epub 2014 Jun 26.
8
MicroPET/SPECT/CT imaging of small animal models of disease.小动物疾病模型的 microPET/SPECT/CT 成像。
Am J Pathol. 2013 Feb;182(2):319-24. doi: 10.1016/j.ajpath.2012.09.025. Epub 2012 Dec 5.
9
PET and SPECT Imaging for the Acceleration of Anti-Cancer Drug Development.用于加速抗癌药物研发的正电子发射断层扫描(PET)和单光子发射计算机断层扫描(SPECT)成像
Curr Drug Targets. 2015;16(6):582-91. doi: 10.2174/1389450116666150330113747.
10
Syntheses and evaluation of carbon-11- and fluorine-18-radiolabeled pan-tropomyosin receptor kinase (Trk) inhibitors: exploration of the 4-aza-2-oxindole scaffold as Trk PET imaging agents.合成与评价碳-11-和氟-18-放射性标记的泛原肌球蛋白受体激酶(Trk)抑制剂:4-氮杂-2-氧吲哚骨架作为 Trk PET 成像剂的探索。
ACS Chem Neurosci. 2015 Feb 18;6(2):260-76. doi: 10.1021/cn500193f. Epub 2014 Nov 10.

引用本文的文献

1
Understanding the in vivo Fate of Advanced Materials by Imaging.通过成像了解先进材料的体内命运。
Adv Funct Mater. 2020 Sep 10;30(37). doi: 10.1002/adfm.201910369. Epub 2020 Apr 6.
2
Evaluation of Rhenium and Technetium-99m Complexes Bearing Quinazoline Derivatives as Potential EGFR Agents.评估含喹唑啉衍生物的铼和锝-99m 配合物作为潜在的 EGFR 制剂。
Molecules. 2023 Feb 14;28(4):1786. doi: 10.3390/molecules28041786.
3
Organometallic small molecule kinase inhibitors - direct incorporation of Re and 99mTc into Opaganib®.

本文引用的文献

1
N-(4-Meth-oxy-phen-yl)-N'-(5-nitro-1,3-thia-zol-2-yl)urea.N-(4-甲氧基苯基)-N'-(5-硝基-1,3-噻唑-2-基)脲
Acta Crystallogr Sect E Struct Rep Online. 2010 Aug 18;66(Pt 9):o2339. doi: 10.1107/S1600536810032186.
2
Synthesis and application of isocyanates radiolabeled with carbon-11.碳-11 标记异氰酸酯的合成与应用。
Chemistry. 2011 Jan 3;17(1):259-64. doi: 10.1002/chem.201002345. Epub 2010 Nov 12.
3
The first design and synthesis of [11C]MKC-1 ([11C]Ro 31-7453), a new potential PET cancer imaging agent.首次设计和合成 [11C]MKC-1([11C]Ro 31-7453),一种新的潜在的正电子发射断层扫描(PET)癌症成像剂。
金属有机小分子激酶抑制剂-奥帕尼布®中 Re 和 99mTc 的直接掺入。
Chem Commun (Camb). 2021 Dec 9;57(98):13349-13352. doi: 10.1039/d1cc03678e.
4
Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma.用于胶质母细胞瘤靶向放射性核素治疗的新型受体酪氨酸激酶途径抑制剂
Pharmaceuticals (Basel). 2021 Jun 29;14(7):626. doi: 10.3390/ph14070626.
5
Radiofluorination of oxazole-carboxamides for preclinical PET neuroimaging of GSK-3.用于糖原合酶激酶-3临床前正电子发射断层显像神经成像的恶唑甲酰胺的放射性氟化
J Fluor Chem. 2021 May;245. doi: 10.1016/j.jfluchem.2021.109760. Epub 2021 Feb 21.
6
The Role of VEGF Receptors as Molecular Target in Nuclear Medicine for Cancer Diagnosis and Combination Therapy.血管内皮生长因子受体作为核医学中癌症诊断与联合治疗分子靶点的作用
Cancers (Basel). 2021 Mar 3;13(5):1072. doi: 10.3390/cancers13051072.
7
Reversal of Global Ischemia-Induced Cognitive Dysfunction by Delayed Inhibition of TRPM2 Ion Channels.延迟抑制 TRPM2 离子通道逆转全脑缺血诱导的认知功能障碍。
Transl Stroke Res. 2020 Apr;11(2):254-266. doi: 10.1007/s12975-019-00712-z. Epub 2019 Jun 28.
8
Emerging PET Radiotracers and Targets for Imaging of Neuroinflammation in Neurodegenerative Diseases: Outlook Beyond TSPO.新兴的PET放射性示踪剂及用于神经退行性疾病神经炎症成像的靶点:超越转运体18 kDa的展望
Mol Imaging. 2018 Jan-Dec;17:1536012118792317. doi: 10.1177/1536012118792317.
9
Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET.PET证实ROS1/ALK抑制剂劳拉替尼可穿透血脑屏障。
Mol Imaging. 2017 Jan-Dec;16:1536012117736669. doi: 10.1177/1536012117736669.
10
Synthesis and preliminary PET imaging of C and F isotopologues of the ROS1/ALK inhibitor lorlatinib.C 和 F 同位素标记物的 ROS1/ALK 抑制剂 lorlatinib 的合成及初步 PET 成像研究。
Nat Commun. 2017 Jun 8;8:15761. doi: 10.1038/ncomms15761.
Nucl Med Biol. 2010 Oct;37(7):763-75. doi: 10.1016/j.nucmedbio.2010.04.186.
4
Radiosynthesis and initial in vitro evaluation of [18F]F-PEG6-IPQA--a novel PET radiotracer for imaging EGFR expression-activity in lung carcinomas.[18F]F-PEG6-IPQA 的放射性合成及初步体外评价——一种用于肺癌中 EGFR 表达-活性成像的新型 PET 放射性示踪剂。
Mol Imaging Biol. 2011 Oct;13(5):853-61. doi: 10.1007/s11307-010-0408-8.
5
Development of a new epidermal growth factor receptor positron emission tomography imaging agent based on the 3-cyanoquinoline core: synthesis and biological evaluation.基于 3-氰基喹啉核心开发新型表皮生长因子受体正电子发射断层扫描显像剂:合成与生物学评价。
Bioorg Med Chem. 2010 Sep 15;18(18):6634-45. doi: 10.1016/j.bmc.2010.08.004. Epub 2010 Aug 6.
6
Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls.放射性标记受体酪氨酸激酶靶向药物用于患者分层和治疗反应监测:前景与挑战。
Lancet Oncol. 2010 Oct;11(10):992-1000. doi: 10.1016/S1470-2045(10)70088-7. Epub 2010 Jul 26.
7
Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease.用于疾病正电子发射断层扫描(PET)和单光子发射计算机断层扫描(SPECT)成像的铜、镓、铟、钇和锆等配位放射性金属。
Chem Rev. 2010 May 12;110(5):2858-902. doi: 10.1021/cr900325h.
8
Vascular endothelial growth factor receptor as target for advanced non-small cell lung cancer therapy.血管内皮生长因子受体作为晚期非小细胞肺癌治疗的靶点。
Curr Drug Targets. 2010 Jul;11(7):865-8784. doi: 10.2174/138945010791320791.
9
Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET.通过小动物 PET 评价改良 PEG-苯胺喹唑啉衍生物作为潜在的 EGFR 成像剂在癌症中的应用。
Mol Imaging Biol. 2010 Dec;12(6):616-25. doi: 10.1007/s11307-010-0315-z.
10
Direct fixation of [(11)C]-CO(2) by amines: formation of [(11)C-carbonyl]-methylcarbamates.胺对 [(11)C]-CO2 的直接固定:[(11)C-羰基]-甲基氨基甲酸酯的形成。
Org Biomol Chem. 2010 Jan 21;8(2):428-32. doi: 10.1039/b916419g. Epub 2009 Nov 18.